NEW YORK , Nov. 19, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global biologics contract development and manufacturing organization (CDMO) market size is estimated to grow by USD 10.63 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 10.46% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards advent of big data.
However, capacity utilization and constraints poses a challenge.Key market players include 3P BIOPHARMACEUTICALS S.L.
U, AbbVie Inc., AGC Biologics, Binex Co. Ltd.
, Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp.
, Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd.
, Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd.
, Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co.
Ltd., and WuXi Biologics Cayman Inc..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Biologics Contract Development and Manufacturing Organization (CDMO) market is experiencing significant growth, particularly in the areas of small molecules and large molecules, including biologics, biosimilars, cancer therapies, monoclonal antibodies, and vaccines. This trend is driven by the increasing demand for sp.
